"10.1371_journal.pone.0065616","plos one","2013-05-31T00:00:00Z","Marloes J M Gooden; Valerie R Wiersma; Douwe F Samplonius; Jurjen Gerssen; Robert J van Ginkel; Hans W Nijman; Mitsuomi Hirashima; Toshiro Niki; Paul Eggleton; Wijnand Helfrich; Edwin Bremer","Department of Surgery, Translational Surgical Oncology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands; Department of Obstetrics and Gynecology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands; GalPharma Co., Ltd., Kagawa, Japan; Department of Immunology and Immunopathology, Kagawa University Faculty of Medicine, Kagawa, Japan; University of Exeter Medical School, Exeter, United Kingdom","Conceived and designed the experiments: DS PE EB WH. Performed the experiments: VW MG DS JG. Analyzed the data: VW EB. Contributed reagents/materials/analysis tools: MH TN PE RVG. Wrote the paper: MG VW EB. Revised the paper: MG VW EB PE HN WH.","The authors have the following interests: Drs. Niki and Hirashima are board members of GalPharma Co., Ltd. The authors have a product in development: stable-form galectin-9. Name of the patent: NOVEL MODIFIED GALECTIN 9 PROTEINS AND USE THEREOF. Patent numbers: EP1736541, JP4792390, US8268324. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","05","Marloes J M Gooden","MJMG",11,TRUE,4,4,2,3,TRUE,FALSE,FALSE,0,NA,FALSE
